Psoriatic Arthritis Trial, Recruiting NCT06586281 Sponsor: University of California, San Diego Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Psoriatic Arthritis Trial, Recruiting

NCT06586281
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult who has been diagnosed with Psoriatic Arthritis (PsA) using a recognised set of medical criteria called CASPAR
  • You have one or more swollen joints and/or one or more painful, tender spots where tendons or ligaments attach to bone (enthesitis)
  • You have one or more raised, scaly skin patches caused by psoriasis
  • Your regular medications have not changed in the last three months, and you have not used steroid tablets or long-term steroid treatments in the last 8 weeks
  • You are overweight or obese, meaning your Body Mass Index (BMI) is 25.0 or above (or 23.0 or above if you are of Asian background)
  • Your doctor (rheumatologist) has already decided to start you on a medication called Guselkumab for your PsA
  • A special scan of your liver shows a higher-than-normal amount of fat in your liver, consistent with a condition called NAFLD (non-alcoholic fatty liver disease), after other liver conditions have been ruled out

Who may not be able to join:

  • You have previously taken certain types of medications for inflammatory conditions, specifically IL-12/23 inhibitors, IL-17 inhibitors, JAK inhibitors, or TYK2 inhibitors, or you have used more than two TNF inhibitor treatments in the past (confirm with trial site)
  • You have Hepatitis B, Hepatitis C, or any other known chronic liver disease from another cause
  • You have certain inherited or immune-related liver conditions such as autoimmune hepatitis, primary biliary cirrhosis, Wilson disease, alpha-1-antitrypsin deficiency, or haemochromatosis (confirm with trial site)
  • You have liver scarring (cirrhosis) or have had complications from serious liver disease such as fluid build-up in the abdomen, confusion caused by liver failure, or enlarged veins in the oesophagus
  • You have had weight-loss bypass surgery or have taken certain medications known to cause liver fat build-up (such as high-dose steroids, tamoxifen, or amiodarone) in the past 6 months
  • You drink alcohol regularly or heavily — more than 30g per day if male, or more than 15g per day if female — and have done so for more than 2 years at any point in the last 10 years
  • Your kidneys are not working well enough, based on a specific blood test result (creatinine above 2.0 mg/dL)
  • You are pregnant, breastfeeding, or planning to become pregnant
  • Your life expectancy is estimated to be less than 5 years
  • You have a known HIV infection

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 8588226523

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 September 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Change in NAFLD severity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov